Association of British Neurologists: Revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

Practical Neurology

Volumn 15, Issue 4, 2015, Pages 273-279

  Scolding, Neil ^a   Barnes, David ^b   Cader, Sarah ^c   Chataway, Jeremy ^d   Chaudhuri, Abhijit ^e   Coles, Alasdair ^f   Giovannoni, Gavin ^g   Miller, David ^d   Rashid, Waqar ^h   Schmierer, Klaus ^g   Shehu, Abdullah ⁱ   Silber, Eli ^j   Young, Carolyn ^k   Zajicek, John ^l  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c Basingstoke Hospital   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e QUEEN S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h Hurstwood Park Neurological Centre   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

^j KING S COLLEGE HOSPITAL   (United Kingdom)

^k ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^l UNIVERSITY OF PLYMOUTH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MANAGEMENT; HUMAN; MULTIPLE SCLEROSIS; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; STANDARDS; UNITED KINGDOM;

DISEASE MANAGEMENT; DRUG PRESCRIPTIONS; GREAT BRITAIN; GUIDELINES AS TOPIC; HUMANS; MULTIPLE SCLEROSIS; PHYSICIANS;

EID: 84937402267     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/practneurol-2015-001139     Document Type: Article

References (31)

1. HSC 2002/004-Cost effective provision of disease modifying therapies for people with Multiple Sclerosis. Health Do. London. 2002.
2. Rice CM. Disease modification in multiple sclerosis: an update. Pract Neurol 2014;14:6-13.
3. Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-16.
4. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14.
5. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
6. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28.
7. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
8. Scalfari A, Neuhaus A, Daumer M, et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol 2013;70:214-22.
9. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8.
10. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
11. Group PS. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
12. The IMSSG. Interferon beta-1b is effective in relapsing-remitting multiple- sclerosis-clinical-results of a multicenter, randomized, double- blind, placebo-controlled trial. Neurology 1993;43:655-61.
13. Panitch H Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-95.
14. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MSSG. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001;56:1496-504.
15. Bermel RA, Weinstock-Guttman B, Bourdette D, et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler 2010;16:588-96.
16. Ebers GC, Traboulsee A, Langdon D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010;81:907-12.
17. Greenberg BM, Balcer L, Calabresi PA, et al. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol 2013;70:248-51.
18. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51.
19. Montalban X, Sastre-Garriga J, Tintore M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009;15:1195-205.
20. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
21. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-9.
22. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
23. Sormani MP, Rio J, Tintore M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013;19:605-12.
24. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
25. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9.
26. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82.
27. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
28. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11.
29. Miller AE,Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:977-86.
30. Kinkel RP, Dontchev M, Kollman C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012;69:183-90.
31. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97.